GAMMA Investing LLC Has $26,000 Position in The Chemours Company (NYSE:CC)

GAMMA Investing LLC grew its position in The Chemours Company (NYSE:CC) by 99.7% during the 4th quarter, Holdings Channel reports. The firm owned 1,532 shares of the specialty chemicals company’s stock after purchasing an additional 765 shares during the quarter. GAMMA Investing LLC’s holdings in Chemours were worth $26,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in CC. Matrix Trust Co bought a new position in Chemours during the 3rd quarter valued at about $25,000. Blue Trust Inc. increased its holdings in shares of Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 731 shares in the last quarter. Truvestments Capital LLC bought a new position in shares of Chemours in the third quarter valued at approximately $35,000. Brooklyn Investment Group acquired a new position in shares of Chemours in the 3rd quarter worth approximately $37,000. Finally, Signaturefd LLC grew its position in Chemours by 163.7% during the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock worth $40,000 after acquiring an additional 1,216 shares during the last quarter. Institutional investors own 76.26% of the company’s stock.

Insider Transactions at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.47% of the stock is owned by corporate insiders.

Chemours Stock Performance

Shares of NYSE:CC opened at $18.79 on Thursday. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The Chemours Company has a 1-year low of $15.10 and a 1-year high of $32.48. The stock has a market capitalization of $2.81 billion, a P/E ratio of 37.58 and a beta of 1.83. The business has a 50-day moving average price of $19.21 and a two-hundred day moving average price of $19.80.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. During the same period in the previous year, the firm posted $0.64 earnings per share. Chemours’s revenue for the quarter was up .9% compared to the same quarter last year. Equities analysts predict that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.32%. The ex-dividend date of this dividend was Friday, November 15th. Chemours’s dividend payout ratio (DPR) is currently 200.00%.

Analysts Set New Price Targets

Several brokerages have issued reports on CC. Morgan Stanley cut their price objective on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday. Barclays lifted their price target on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Mizuho decreased their price objective on shares of Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets raised their price objective on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, October 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $23.75.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.